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PURPOSE—While the diagnostic success of genomic sequencing expands, the complexity of 
this testing should not be overlooked. Numerous laboratory processes are required to support the 
identification, interpretation and reporting of clinically significant variants. This study aimed to 
examine workflow and reporting procedures among US laboratories to highlight shared practices 
and identify areas in need of standardization.
METHODS—Surveys and follow-up interviews were conducted with laboratories offering exome 
and/or genome sequencing, to support a research program or for routine clinical services. The 73-
item survey elicited multiple choice and free text responses, later clarified with phone interviews.
RESULTS—Twenty-one laboratories participated. Practices highly concordant across all groups 
included: consent documentation, multi-person case review, and enabling patient opt-out of 
incidental or secondary findings analysis. Noted divergence included use of phenotypic data to 
inform case analysis and interpretation, and reporting of case-specific quality metrics and 
methods. Few laboratory policies detailed procedures for data reanalysis, data sharing or patient 
access to data.
CONCLUSION—This study provides an overview of practices and policies of experienced 
exome and genome sequencing laboratories. The results enable broader consideration of which 
practices are becoming standard approaches, where divergence remains, and areas development of 
best practice guidelines may be helpful.
Keywords
exome sequencing; genome sequencing; laboratory standards; genetic testing; clinical reporting
INTRODUCTION
Exome sequencing is rapidly gaining acceptance as a useful diagnostic test in clinical 
medicine1,2,3. While a less frequently utilized option, genome sequencing enables more 
comprehensive genome analysis with expanded data and uniform depth of coverage, albeit at 
higher cost and lower average depth of coverage4,5. With each of these tests, collectively 
referred to here as “genomic sequencing,” there are numerous laboratory processes required 
to support the identification, interpretation and reporting of variants that may be clinically 
significant for the patient.
A typical genome has about 3.5 million differences when compared to the reference 
genome, of which 0.6 million are rare or novel6. Although exome sequencing focuses on the 
subset of variants within or near coding sequences, hundreds to thousands of variants are 
identified for analysis per patient for clinical relevance7. A major challenge is determining 
which, if any, of the identified variants may be relevant to the indication for testing and 
thereby warrant inclusion in the final test report. Beyond variants of possible diagnostic or 
therapeutic relevance, laboratories may also choose to identify incidental or secondary 
variants unrelated to the testing indication (referred to below as “secondary findings”), but 
potentially relevant to the patient and their family’s health. Unquestionably, the inclusion or 
exclusion of variants in test reports may have substantial impact on patient care. It is 
therefore of critical importance to explore how these decisions are made.
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Laboratories and professional societies have begun developing and recommending 
approaches to support this complex and labor-intensive process, which combines the practice 
of medicine with burgeoning next generation sequencing (NGS) laboratory 
procedures8,9,10,11,12. Here we present the results from a survey of laboratories experienced 
in genomic sequencing to explore protocols supporting the testing, interpretation and 
reporting processes. The goal of this study was to identify workflow and reporting practices 
that are shared and/or discordant among laboratories in an effort to highlight practices that 
are becoming standard and to determine areas in need of standardization or best practice 
recommendations.
METHODS
Recruitment
US laboratories that are Clinical Laboratory Improvement Amendments (CLIA)-certified 
and offer exome and/or genome sequencing, either to support the National Human Genome 
Research Institute (NHGRI) and National Cancer Institute (NCI) funded Clinical 
Sequencing Exploratory Research (CSER) program13 or for routine clinical services, were 
invited to participate in the survey. Clinical services outside of CSER were primarily 
identified through a search of NCBI’s Genetic Test Registry (http://www.ncbi.nlm.nih.gov/
gtr/). A total of 27 laboratory groups were identified. An invitation letter describing the 
purpose of the survey was sent by email to each laboratory. One follow-up invitation was 
sent to non-responding laboratories. Of the 27 laboratories contacted, 21 responded and 
completed participation (78% response rate) (Table 1).
Participation was completely voluntary and laboratories did not receive compensation for 
completion of the study. This study was submitted to the Partners HealthCare IRB for review 
on October 12th 2014 and determined to be exempt. Consent was implied by agreement to 
participate.
Surveys
A 73-item survey was developed by the study team with input from the CSER Actionability 
and Return of Results Working Group (see Supplementary Materials and Methods). Items 
were formatted as multiple-choice with the option to provide free text and were grouped 
topically including the following elements of genomic sequencing laboratory processes:
Consent Time required for variant and case review
Sample (Trio vs. Proband-only) Sanger confirmation
Phenotype collection Provision of gene/region coverage statistics
Indication-specific gene list development and use Secondary findings policy
Credentials of staff for various roles Reanalysis of data
Case review, group discussion and clinician input Return of raw data policies
The survey was emailed to each laboratory group who identified staff that were key 
informants regarding the laboratory’s sequencing, interpretation and reporting processes. 
Surveys were completed between December 2014 and February 2015. Study leads (HMM, 
JMO and HLR) reviewed the completed survey through a follow-up phone call with each 
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laboratory’s primary respondents, enabling clarification of questions and answers. Each 
follow-up call lasted approximately 1 hour and was audio-recorded.
Data Analysis
Due to the small sample size, only frequency counts and descriptive results were utilized to 
demonstrate trends of agreement or divergence among the CSER program and clinical 
service laboratories. Counts are combined for clinical and CSER laboratories when 
responses do not appear to differ between the settings.
RESULTS
Participants
Responses were collected from CLIA-certified laboratories offering exome and genome 
sequencing, including nine of the ten laboratories supporting CSER research programs as 
well as twelve laboratories offering routine clinical genomic services, for a total of 21 
laboratories. All responses represented practices at the time of survey completion. Some 
laboratories supported both a routine clinical service and a CSER program. However, these 
laboratories usually had separate protocols (and in some cases different personnel) specific 
to each purpose. For the purposes of this study, these approaches were treated as two 
separate laboratories. Hereafter the laboratories offering routine clinical services will be 
referred to as “clinical” laboratories (N=12) and the laboratories supporting research 
programs will be referred to as “CSER” laboratories (N=9) (Table 1).
Overall, 16 laboratories (out of 21) reported a history of completing >50 exome or genome 
sequencing tests, and a high proportion of clinical laboratories (8 of the 12) had completed 
>200 tests at the time of the survey.
Sample and Consent
All laboratories required written documentation of consent prior to performing the test, with 
some variance in whether it was signed by the patient only (12 of 21), or the patient and 
physician (9 of 21).
The majority of clinical laboratories (8 of 12) performed genome- or exome-scale testing on 
trio samples in >50% of cases, whereas the opposite was true of CSER laboratories, with 6 
of 9 sequencing probands only.
Phenotype Collection and Target Gene List Development
Phenotypic information was collected from the referring clinician through several means, the 
most frequent of which were: free text fields on the requisition form (14 of 21), attached 
medical records and clinic notes (14 of 21) and via written responses to targeted questions 
(13 of 21). Only one CSER laboratory did not collect any phenotypic information due to 
their primary project aim of carrier status rather than diagnostic analysis.
There was notable variance in how frequently laboratories reported using indication-specific 
gene lists for targeted analysis of individual cases: 10 of the 21 laboratories used them in all 
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or almost every case (>90–100%); 4 in the majority (50–90%) of cases; 1 in 10–50% of 
cases; and 6 rarely (<10%) or never used them. For three of the laboratories, the same gene 
list was applied for all cases due to the test indication: carrier status analysis or oncology 
(somatic and germline) testing. Most laboratories that used indication-based gene lists did 
not have a policy governing how lists were developed or updated, though two clinical 
laboratories reported gene lists were assembled on a case-by-case basis.
Case Review
Variant interpretation and case review processes include several steps, and laboratories 
identified individuals with various roles in these processes (Figure 1). For the purpose of this 
survey, we defined the initial analysis as the non-automated primary collection of variant-
level evidence for case-specific clinical interpretation. This initial analysis was most 
frequently performed by PhD-level analysts or fellows (Medical Genetics or Pathology), and 
genetic counselors were also frequently involved. Although some laboratories involved 
American Board of Medical Genetics and Genomics (ABMGG) board-certified medical 
geneticists (PhD trained) or pathologists in the initial analysis steps, these individuals were 
most often utilized in secondary review and report sign-out.
Group discussion was frequently employed within the process of variant review for potential 
case-specific relevance and all but one laboratory had regularly scheduled meetings for this 
purpose. This clinical laboratory instead conducted ad hoc meetings for an estimated 10–
50% of cases. Approximately 60% of laboratories (12 of 21) reported group discussion is 
part of all or almost every case (90–100%) (6 clinical; 6 CSER), whereas 3 clinical 
laboratories utilized group discussion for only a small portion (<10%) of cases. The make-
up of professionals in the group discussions nearly always involved board-certified medical 
and clinical geneticists, genetic counselors, and bioinformaticians, but also commonly 
included basic science researchers, non-genetics physicians, trainees and ethicists.
Exclusive of group discussions, more than one individual was involved in the interpretation 
and reporting of each case: 7 laboratories (4 clinical; 3 CSER) typically utilized two 
individuals, 9 laboratories (4 clinical; 5 CSER) utilized three individuals, and 5 laboratories 
(4 clinical; 1 CSER) reported ≥ four individuals were involved in each case. No laboratories 
reported using only one individual per case.
The time required for full case review was predominantly based on estimates rather than 
timed work and varied widely among groups (see Supplemental Figure S1 and S2).
Sanger Confirmation
Sanger sequencing was used for orthogonal confirmation by the majority of laboratories (17 
of 21) for all reported variants or for variants considered to represent possible diagnostic 
findings (Figure 2). Only one clinical lab indicated they did not confirm any reported 
variants. Most laboratories had protocols specifying which types of reported variants were or 
were not Sanger confirmed. For example, in one laboratory, only the germline variants were 
confirmed when paired somatic/germline sequencing was performed. Another laboratory 
chose not to confirm reported variants related to pharmacogenetics, carrier status or low 
penetrant genetic risk associations. Yet another confirmed only those variants that clearly 
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matched the clinical indication question, whereas, if a particular variant(s) explained only 
one of several clinical features, it would not be confirmed. Notably, the survey did not elicit 
analytical quality thresholds used in the decisions of which variants to review, focusing 
instead on policies regarding how different types of variants are handled.
Sequencing Test Report
Variant classes included in the report were influenced by whether the variant was relevant to 
manifesting symptoms or considered a secondary finding. In regards to diagnostic 
indications, 19 of 20 laboratories reported variants deemed pathogenic or likely pathogenic 
as well as variants of uncertain significance (VUSs) if related to manifesting symptoms. 
None of the clinical laboratories returned VUSs for secondary findings, though, two CSER 
laboratories did, consistent with their research goals. Three laboratories included likely 
benign or benign variants on the test report for diagnostic findings.
Case-specific filtering strategies, including gene lists, were used by most laboratories during 
analysis for at least a portion of cases to facilitate identification of potentially relevant genes/
variants. In addition, case-specific data quality and exon coverage for phenotypically 
relevant genes may be considered during case analyses. Interestingly, 4 of 15 laboratories 
that reported use of phenotypically derived gene lists in at least a portion of cases indicated 
that such methods were not regularly communicated in the test report, though one laboratory 
would make them available by request. Further, case-specific coverage of genes, regardless 
of whether a gene list was used, was not universally conveyed. Ten of 21 laboratories 
routinely reported case-specific coverage and an additional 4 laboratories made it available 
separately or by request.
Secondary Findings
All laboratories indicated that they report secondary findings; however, there was 
considerable variability in the types of secondary findings reported and whether patients 
were allowed to “opt-out” of receiving them (Table 2). Eight clinical laboratories allowed 
patients to opt-out of receiving these results, whereas four of the clinical laboratories 
required “opt-in” for secondary findings reflecting deliberate patient choice. Of the CSER 
laboratories, one targeted to healthy participants did not allow opt-out of any findings, seven 
allowed opt-out of all secondary findings, and one required disclosure for a predefined set of 
genes while requiring opt-in to learn additional subsets. It is noted that the specific aims of 
each study influenced CSER laboratory approaches towards return of secondary findings and 
that the CSER protocols were likely written prior to the publication of the ACMG 
guidelines12,14.
Five clinical laboratories limited secondary finding variant analysis and reporting principally 
to the 56 genes recommended for return by the American College of Medical Genetics and 
Genomics (ACMG)12, though three of these reported additional “medically actionable 
findings” incidentally discovered in the course of the primary diagnostic analysis. Another 
clinical lab only reported variants within the ACMG 56 genes if they were discovered in the 
course of the primary diagnostic analysis. The number of genes included for analysis and 
return ranged from the ACMG 56 to “any human disease gene” (>4500 genes) and included 
O’Daniel et al. Page 7
Genet Med. Author manuscript; available in PMC 2017 May 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
categories such as monogenic disease, carrier status, pharmacogenomic variants, complex 
traits and blood antigen prediction. Again, research aims influenced the number and 
categories for CSER laboratories as exemplified by one that did not analyze four of the 
ACMG genes that caused childhood-onset conditions (RB1, WT1, APOB and PCSK9) 
because their study enrolled only adults, but added 50 additional adult-onset medically 
actionable genes to their list.
Reanalysis
The majority of laboratories indicated that they had reanalyzed case-specific data to provide 
an updated report at least once (11 of 12 clinical and 4 of 9 CSER). The instances were rare, 
however, with 7 of 12 clinical and 6 of 9 CSER laboratories indicating that reanalysis rarely 
or never occurred. Only one clinical laboratory routinely reanalyzed every case. When 
reanalysis was performed, roughly half used the existing variant call format (VCF) file and 
half performed new alignment and variant calling. Of the clinical laboratories, six indicated 
reanalysis would be free of charge, five charged a fee, and one was still developing its 
policy.
Raw Data Return
The US Department of Health and Human Services issued a rule change that went into effect 
in April 2014 specifying that clinical laboratories must provide copies of completed test 
reports to the patient upon request15. At the time of survey collection, there was some 
question as to what types of data this encompassed16. When queried about this new rule, 
three clinical laboratories indicated they would return uninterpreted sequencing data to 
patients and/or physicians upon request, whereas eight clinical laboratories would return it 
only to the physician. The frequency of actually doing this was low, however; one clinical 
laboratory had returned such data to patients (< 10% of cases). Return to physicians was 
more frequent, with four returning it in 10–50% of cases and four returning it for less than 
10% of cases. Laboratories indicated a fee may be charged to offset costs associated with 
storage devices, shipping, and other expenses.
DISCUSSION
The results of our exploratory survey revealed numerous areas of convergence across 
laboratories, suggesting practices that may represent a developing standard for exome and 
genome sequencing. Examples include consent documentation, default inclusion of some 
secondary findings as well as allowing some choice, and case review by more than one 
individual. There were also some notable areas of divergence that warrant further discussion 
and possible clarification through practice guideline development.
Clinical NGS guidelines recommend detailed phenotypic information to aid the laboratory 
analysis and interpretation process10. Consistent with this recommendation, phenotypic data 
about the clinical indication(s) for testing were collected by all laboratories in various 
formats. The creation of phenotype-guided gene lists for defining high-priority genes was 
not uniformly used during the bioinformatic filtering steps. While many cases may be solved 
without such gene lists, the prioritized review of variants in genes most likely to be 
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implicated enables further in-depth consideration of variants in higher likelihood genes to 
ensure they are not overlooked. The absence of these approaches in some laboratories may 
reflect the diversity of bioinformatics pipelines employed or other strategies to incorporate 
phenotype. It is also worth noting that if phenotypic assumptions are incorrect, over-reliance 
on gene lists could cause a clinically relevant variant to be missed. Continued 
standardization of analysis pipelines, robust methods and standardized ontologies for 
phenotypic collection, and the development of high quality curated gene-phenotype datasets 
are important to the assurance of comprehensive, consistent case analysis.
In conflict with sequencing guidelines, case-specific analysis approaches (e.g. 
phenotypically guided gene lists) were not routinely communicated through the test report10. 
When these analysis details are omitted from the report, it may be unclear to the clinician 
which genes were/were not analyzed for their patient or how well any particular gene was 
covered. This information would be of highest importance in the case of a negative result. 
Failing to provide a clear depiction of gene-centric analysis and coverage could lead to false 
assumptions by the ordering clinician that key genes had been ruled out.
Another area of discordance is revealed in laboratories’ use of group discussion in the case 
review process. Although all laboratories reported that more than one individual was 
involved in the analysis and interpretation of a given case, little more than half routinely 
utilized group review for most cases. Benefits of group discussion or solicitation of ad hoc 
expertise include the insight from multiple perspectives and expertise including 
bioinformatics8, basic science, and clinical domain knowledge17. This ‘peer-review’ may 
improve accuracy and confidence in decision-making regarding the potential clinical 
relevance of variants18. Case volume, time demands and costs are obvious constraining 
factors for implementing group case review, as is solicitation of disease area expertise. It 
may be practical for experienced laboratories to consider this approach only in particularly 
challenging cases.
Most laboratories were in agreement about which variant classification categories warranted 
inclusion on the clinical report. However, policies governing the confirmation of reported 
variants, typically through Sanger sequencing, differed somewhat from lab to lab. Notably, 
one clinical lab indicated that they do not confirm any variants, and several others had 
certain categories of reported variants that were not confirmed. While it has been generally 
recommended that laboratories Sanger confirm reported germline variants10, as laboratories 
gain experience with the analytic performance of NGS, there is increasing movement 
towards defining thresholds for quality (and perhaps clinical significance) for which such 
confirmation is unnecessary19,20,21.
Survey results indicated that reanalysis of data remains predominantly an ad hoc service 
performed on request, rather than an integrated process. Several factors may play a role in 
this absence of common practice, including the rapid pace at which new genetic knowledge 
is generated as well as the relatively new addition of exome and genome testing services 
(many clinical exome sequencing services are less than three years old). Another important 
driver is likely the lack of the billing reimbursement infrastructure needed to support data 
reanalysis, interpretation and reporting22.
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In 2014, new Federal rules issued by the US Department of Health and Human Services 
(DHHS) specified that clinical laboratories are required to provide copies of completed test 
reports directly to the patient upon request15. January 2016 guidance from DHHS clarified 
that for genomic tests, the access right includes “a copy of the completed test report, the full 
gene variant information generated by the test, as well as any other information in the 
designated record set concerning the test”23. A major aim of the rule and guidance is to 
grant individuals access to their protected health information maintained by providers. 
Likely due in part to the uncertainty regarding the rule, it is interesting to note that the 
majority of laboratories reported they would release uninterpreted or unvalidated sequence 
data to the ordering physician only. Despite the recent 2016 clarification, guidance may be 
welcomed by the laboratory community on how best to effectuate this right of access. The 
customary practice in medicine has been to convey medical data through a patient’s 
clinician, who can interpret its significance in the appropriate clinical context as 
uninterpreted and unvalidated data would likely be inaccessible to direct interpretation by 
most patients. Laboratory practices are likely to continue to evolve as patients are taking an 
increasingly active role in their health and exercising their right to advance medicine through 
data sharing. Laboratories and clinicians may perceive some risks both professional (if 
subsequent analyses were to conflict with the original assessment) and resource related due 
to this type of data return. It is, however, critical that we as professionals maintain 
transparency and support peer review of our practices to ensure the highest quality care be 
delivered to patients.
Limitations
Given the rapid evolution of genomic sequencing practices, the testing market, and legal 
rules, as well as < 100% response from all laboratories at the time of this survey, these 
results may not reflect current exome and genome sequencing practices. All respondents 
reviewed the data for accuracy and major changes immediately prior to submission, 
however. Further, these results do not reflect practices outside the US and the majority of 
laboratories represented were primarily academic institutions, many of which may have had 
practices influenced by specific grant funding for clinical sequencing. Furthermore, because 
the survey review was conducted by respondents’ professional peers, it is possible some 
responses may have been impacted by perceived best practices. Lastly, this study provides 
observational data about current practices. There remains a need, however, for systemic 
evidence collection to define the clinical validity and utility of genomic sequencing such that 
recommended best practices can be better informed by underlying evidence.
CONCLUSIONS
This study provides an overview of general practices and policies of experienced exome and 
genome sequencing laboratories. The results enable broader consideration of which practices 
are becoming standard approaches and where development of best practice guidelines may 
be helpful. Notable areas for improvement include:
1. Transparency and clarity regarding test methods and limitations. We 
recommend that the scope of analysis (including the use of gene lists), case-
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specific coverage metrics, and analytical limitations, should be communicated 
with the report. Information might include:
a. List of genes targeted for analysis and the phenotype elements used to 
select them;
b. Stated threshold for minimum coverage and notation when coverage of 
a targeted gene falls below that threshold; and/or
c. Known pathogenic variation relevant to the indication but not detectable 
by the test.
2. Utilization of clinical domain expertise in case review. We suggest that 
laboratories consider implementing group case review with inclusion of varied 
expertise including clinical domain expertise. While not necessary for all cases, 
laboratories may wish to define circumstances in which group review is critical 
for improved case-specific determination of clinically relevant variants to report, 
as well as to provide a rich learning environment for all staff.
3. Confirmation of reported variants. We recommend that all variants reported to 
have potential diagnostic significance must reach a defined threshold for data 
quality or require confirmation by an orthogonal method. This should apply to 
both indication-specific and secondary finding variants likely to be used in 
clinical care. This would not apply to the return of uninterpreted sequence data 
addressed below under data access.
4. Data access guidelines. Federal rules and guidance now establish a patient’s 
right of access to “the completed test report, the full gene variant information 
generated by the test, as well as any other information in the designated record 
set concerning the test.” We suggest that the professional community establish 
guidelines surrounding the return of sequencing data directly to patients to guide 
laboratories in honoring patients’ right of access while minimizing potential 
harm from misunderstood or incorrectly interpreted results.
5. Data reanalysis. We recommend laboratories develop internal genomic 
sequencing data reanalysis guidelines. These guidelines are best informed by the 
professional community and should address both laboratory-initiated reanalysis 
and clinician-initiated reanalysis as well as the appropriate data to be reanalyzed 
(existing VCF vs. raw data requiring new alignment and base calling vs. new 
sequencing run) and when re-testing would be recommended over reanalysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Type of individual who performs initial interpretive analysis of variants after bioinformatics 
filtering
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Figure 2. 
Types of variants for which Sanger confirmation routinely occurs
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Table 1
List of participating laboratories
CSER (n=9) Clinical (n=12)
Exome Only
BASIC3 (Baylor) Ambry Genetics
CanSeq (DFCI) Baylor Miraca Genetics
NCGENES (UNC) The Children’s Hospital of Philadelphia (CHOP)
NEXT Medicine (UW) Columbia University Medical Center
PediSeq (CHOP) Emory
GeneDx
University of California Los Angeles
University of Chicago
Genome Only
Kaiser Permanente Illumina
MedSeq
Exome & Genome
HudsonAlpha Medical College of Wisconsin
MI-ONCOSEQ (U. Michigan)* Partners Laboratory for Molecular Medicine
Personalis
*Genome performed for only a subset
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